ConductScience.org, home

Paper27042004

Selective use of sorafenib in the treatment of thyroid cancer.

Pitoia F and 1 other. Drug Des Devel Ther, 2016. Cited by 50 papers, by iCite.

Cite this record

ConductScience Library. Selective use of sorafenib in the treatment of thyroid cancer. Papers, record 27042004. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27042004

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Selective use of sorafenib in the treatment of thyroid cancer.
PubMed
Journal
Drug Des Devel Ther
PubMed
Year
2016
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
50
iCite
Relative citation ratio, by iCite
1.65
iCite
Revised in PubMed
2024-03-25
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pitoia FFabián
2Jerkovich FFernando

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
NiacinamideMajor topic
Phenylurea CompoundsMajor topic
Thyroid NeoplasmsMajor topic
Cell Proliferation
Humans
Sorafenib

Source PubMed

Download CSV of topics

References85

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117940185BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.Endocr Rev2007https://conductscience.org/library/papers/17940185PubMed
220368568Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.J Clin Oncol2010https://conductscience.org/library/papers/20368568PubMed
321296855Global cancer statistics.CA Cancer J Clin2011https://conductscience.org/library/papers/21296855PubMed
419103722Tyrosine kinase inhibitors and modifications of thyroid function tests: a review.Eur J Endocrinol2009https://conductscience.org/library/papers/19103722PubMed
519451442Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.J Clin Oncol2009https://conductscience.org/library/papers/19451442PubMed
624617711TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.J Clin Endocrinol Metab2014https://conductscience.org/library/papers/24617711PubMed
725572389Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.Eur J Endocrinol2015https://conductscience.org/library/papers/25572389PubMed
818650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
919773371Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.Eur J Endocrinol2009https://conductscience.org/library/papers/19773371PubMed
1024795243Definition and management of radioactive iodine-refractory differentiated thyroid cancer.Lancet Diabetes Endocrinol2014https://conductscience.org/library/papers/24795243PubMed
1119097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
1216303836Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.J Clin Endocrinol Metab2006https://conductscience.org/library/papers/16303836PubMed
1324780046High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.J Clin Endocrinol Metab2014https://conductscience.org/library/papers/24780046PubMed
1424728162Response to sorafenib treatment in advanced metastatic thyroid cancer.Arq Bras Endocrinol Metabol2014https://conductscience.org/library/papers/24728162PubMed
1517519900Mechanisms of adverse effects of anti-VEGF therapy for cancer.Br J Cancer2007https://conductscience.org/library/papers/17519900PubMed
1625029414Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.J Clin Endocrinol Metab2014https://conductscience.org/library/papers/25029414PubMed
177529046The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2.Genes Chromosomes Cancer1994https://conductscience.org/library/papers/7529046PubMed
1823125304Sorafenib therapy decreases the clearance of thyrotropin.Eur J Endocrinol2013https://conductscience.org/library/papers/23125304PubMed
1922033631Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.Ann Surg Oncol2012https://conductscience.org/library/papers/22033631PubMed
2019942992Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer.Arq Bras Endocrinol Metabol2009https://conductscience.org/library/papers/19942992PubMed

See all 85 referencesDownload CSV of references

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.

PMIDTitleJournalYearIn PapersSource
42688036Transcriptomic profiling of thyroid eye disease orbital fibroblasts identifies sorafenib as a novel therapeutic.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42688036PubMed
41642503Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer.Curr Oncol Rep2026https://conductscience.org/library/papers/41642503PubMed
40647542Oncogenic Activity and Sorafenib Sensitivity of ARAF p.S214C Mutation in Lung Cancer.Cancers (Basel)2025https://conductscience.org/library/papers/40647542PubMed
39790707Exploring oncology treatment strategies with tyrosine kinase inhibitors through advanced 3D models (Review).Med Int (Lond)2025https://conductscience.org/library/papers/39790707PubMed
39109434Anti-proliferation evaluation of new derivatives of indole-6-carboxylate ester as receptor tyrosine kinase inhibitors.Future Med Chem2024https://conductscience.org/library/papers/39109434PubMed
38298714Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.Heliyon2024https://conductscience.org/library/papers/38298714PubMed
37513950Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides as Potential Multi-Target Antiproliferative Agents.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37513950PubMed
37323919Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats.Saudi Pharm J2023https://conductscience.org/library/papers/37323919PubMed
36983412Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer.J Clin Med2023https://conductscience.org/library/papers/36983412PubMed
36003403
Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review.
Front Immunol2022https://conductscience.org/library/papers/36003403PubMed
35680841Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression.Cell Death Discov2022https://conductscience.org/library/papers/35680841PubMed
35630083Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review.Medicina (Kaunas)2022https://conductscience.org/library/papers/35630083PubMed
35445315Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.Cancer Chemother Pharmacol2022https://conductscience.org/library/papers/35445315PubMed
35335280Enhancing the Anticancer Activity of Sorafenib through Its Combination with a Nitric Oxide Photodelivering β-Cyclodextrin Polymer.Molecules2022https://conductscience.org/library/papers/35335280PubMed
35281942Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches.Front Pharmacol2022https://conductscience.org/library/papers/35281942PubMed
34984230Rationale for therapeutic decision-making in locally advanced and metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer, starting from a clinical case.Arch Clin Cases2021https://conductscience.org/library/papers/34984230PubMed
34335481Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.Front Endocrinol (Lausanne)2021https://conductscience.org/library/papers/34335481PubMed
34239388Metastatic Papillary Thyroid Cancer to the Liver: The Central Role of a Multidisciplinary Approach to Treatment.Ochsner J2021https://conductscience.org/library/papers/34239388PubMed
33655469YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.Cell Oncol (Dordr)2021https://conductscience.org/library/papers/33655469PubMed
33622865Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma Cells In Vitro.In Vivo2021https://conductscience.org/library/papers/33622865PubMed

See all 35 cited byDownload CSV of cited by

Genes23

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CALCA796PubTator's text mininghttps://conductscience.org/library/genes/796NCBI Gene
CYP3A41576PubTator's text mininghttps://conductscience.org/library/genes/1576NCBI Gene
EDN11906PubTator's text mininghttps://conductscience.org/library/genes/1906NCBI Gene
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
NCOA48031PubTator's text mininghttps://conductscience.org/library/genes/8031NCBI Gene
NRAS4893PubTator's text mininghttps://conductscience.org/library/genes/4893NCBI Gene
PDGFRB5159PubTator's text mininghttps://conductscience.org/library/genes/5159NCBI Gene
PIK3CD5293PubTator's text mininghttps://conductscience.org/library/genes/5293NCBI Gene
PTCH15727PubTator's text mininghttps://conductscience.org/library/genes/5727NCBI Gene
RAF15894PubTator's text mininghttps://conductscience.org/library/genes/5894NCBI Gene
RET5979PubTator's text mininghttps://conductscience.org/library/genes/5979NCBI Gene
SLC16A26567PubTator's text mininghttps://conductscience.org/library/genes/6567NCBI Gene
SLC5A56528PubTator's text mininghttps://conductscience.org/library/genes/6528NCBI Gene
TERT7015PubTator's text mininghttps://conductscience.org/library/genes/7015NCBI Gene

See all 23 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/27042004

GET https://conductscience.org/api/papers/v1/27042004/references?page=2